|Brand Name:||Atenodip SR|
|Generic:||Atenolol + Nifedipine|
|Weight:||50 mg+20 mg|
|Type:||Capsule (Sustained Release)|
|Therapeutic Class:||Combined antihypertensive preparations|
|Manufacturer:||Incepta Pharmaceuticals Limited|
|Last Updated:||2020-11-22 18:15:00|
Atenodip SR Capsule (Sustained Release) contains Atenolol + Nifedipine. Atenodip SR uses:
Management of hypertension where therapy with either a calcium channel blocker or a beta-blocking drug proves inadequate.
Management of chronic stable angina pectoris where therapy with calcium channel blocker or a β-adrenoceptor blocking drug proves inadequate.
Atenodip SR Capsule (Sustained Release) contains Atenolol + Nifedipine 50 mg+20 mg. Atenodip SR doses:
Elderly: Dosage should not exceed 1 capsule daily in hypertension or 1 capsule twice daily in angina.
Pediatric: Safety and effectiveness in pediatric patients have not been established.
The following undesired events have been reported:
Atenolol belongs to a group of medicines called beta-blockers. It has an effect on the heart by blocking the action of chemicals called noradrenaline and adrenaline on beta receptor and control its rate and rhythm of beating. By reducing the heart rate and the force of muscle contraction, atenolol reduces the need of heart muscle for oxygen (demand). Because angina occurs when oxygen demand of the heart exceeds supply, atenolol is helpful in treating angina.
Nifedipine belongs to a group of medicines called calcium-channel blockers. These medicines block the transport of calcium, via holes called channels, into the smooth muscle cells lining the heart blood vessels and other blood vessels of the body. Blocking calcium transport relaxes the muscles of the blood vessels and makes them wider.
Due to its beta-blocker component this combination may increase the number and duration of angina attacks in patients with Prinzmetal's angina due to unopposed alpha receptor mediated coronary artery vasoconstriction. Due to its negative effect on conduction time, caution must be exercised if it is given to patients with first degree heart block.
This combination must not be used in conjunction with calcium channel blockers with negative inotropic effects. eg. verapamil, diltiazem. Concomitant therapy with additional dihydropyridines, e.g. nifedipine, may increase the risk of hypotension, and cardiac failure may occur in patients with latent cardiac insufficiency.
Contraindicated in women capable of childbearing or during pregnancy or during lactation.
This combination should not be used in patients with any of the following conditions: known hypersensitivity to either active component, or any other excipient or other dihydropyridines. Bradycardia; cardiogenic shock; hypotension; metabolic acidosis; severe peripheral arterial circulatory disturbances; second or third degree heart block; sick sinus syndrome; untreated phaeochromocytoma; uncontrolled heart failure; women capable of childbearing or during pregnancy or during lactation; patients with clinically significant aortic stenosis; patients with marked renal impairment. This combination should not be used for secondary prevention of myocardial infarction.
Use in Children: Safety and effectiveness in pediatric patients have not been established.
Symptoms: Bradycardia, hypoglycaemia, bronchospasm, hypotension and acute cardiac failure.
Treatment: Unabsorbed drug may be removed by gastric lavage, activated charcoal and a laxative. Symptomatic treatment may be required.
Store in a cool and dry place protected from light and moisture.
Atenodip SR Capsule (Sustained Release) price in Bangladesh 0.00